CGP 42112A

a hexapeptide analog of angiotensin II; activation of Receptor, Angiotensin, Type 2 results in vasodilation

Also Known As:

CGP 42112; CGP 42112B; CGP-42112; CGP-42112A; CGP42112; CGP42112A; nicotinic acid-Tyr-(N(sigma)-benzyloxycarbonyl-Arg)Lys-His-Pro-Ile-OH; nicotinic acid-tyrosyl-(N(sigma)-benzyloxycarbonyl-arginyl)lysyl-histidyl-prolyl-isoleucine-OH

Networked: 39 relevant articles (4 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - CGP 42112A: 39

Experts

1.	Widdop, Robert E: 5 articles (02/2020 - 04/2009)
2.	Jones, Emma S: 3 articles (02/2020 - 08/2012)
3.	Vinh, Antony: 3 articles (11/2013 - 04/2009)
4.	Gaspari, Tracey A: 2 articles (02/2020 - 11/2013)
5.	Ali, Quaisar: 2 articles (11/2013 - 03/2011)
6.	Hussain, Tahir: 2 articles (11/2013 - 03/2011)
7.	Gao, Lie: 2 articles (10/2013 - 10/2008)
8.	Callaway, Jennifer K: 2 articles (12/2012 - 04/2009)
9.	McCarthy, Claudia A: 2 articles (12/2012 - 04/2009)
10.	Sobey, Christopher G: 2 articles (12/2012 - 08/2012)

Related Diseases

1.	Infarction (Infarctions) 12/01/2012 - "CGP42112 given over 4 doses in the same rats (3 µg/kg per dose centrally) at 6, 24, 48, and 72 hours after stroke induction reduced total infarct volume (32 ± 13 mm(3) versus vehicle, 170 ± 49 mm(3); P<0.05) and improved motor function. " 08/24/2012 - "Mice treated with CGP42112 (1 mg/kg i.p.) after cerebral ischemia had improved functional outcomes over vehicle-treated mice as well as reduced total and cortical infarct volumes. " 08/24/2012 - "Furthermore, systemic administration of CGP42112 can reduce functional deficits and infarct volume following cerebral ischemia in vivo." 04/01/2009 - "Based on infarct, behavioral, and immunohistochemical data, these results indicate that centrally administered CGP42112 exhibits a neuroprotective effect, which was independent of blood pressure. " 07/01/2016 - "In the CGP42112 group, AT2R expression increased, the infarct area decreased, interleukin-1β and tumor necrosis factor-α expression decreased, and interleukin-10 expression increased compared with the saline group. "
2.	Neointima 12/01/1992 - "CGP 42112A was as effective in preventing neointima formation as perindopril (-73%, p < 0.01, versus -76%, p < 0.01, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)" 12/01/1994 - "CGP 42112A (1 mg/d) did not change the neointima-media ratio, indicating that angiotensin subtype 2 receptors were not involved in myointimal hyperplasia in rabbits. "
3.	Stroke (Strokes) 12/01/2012 - "CGP42112 given over 4 doses in the same rats (3 µg/kg per dose centrally) at 6, 24, 48, and 72 hours after stroke induction reduced total infarct volume (32 ± 13 mm(3) versus vehicle, 170 ± 49 mm(3); P<0.05) and improved motor function. " 04/01/2009 - "Spontaneously hypertensive rats were treated with either CGP42112 (0.1 to 10 ng/kg/min intracerebroventricularly) alone or in combination with the AT(2)R antagonist PD123319 (36 ng/kg/min intracerebroventricularly) beginning 5 days before stroke induction. " 04/01/2009 - "Therefore, we have examined the neuroprotective effect of AT(2)R stimulation after intracerebroventricular administration of AT(2)R agonist CGP42112 in a conscious rat model of stroke. "
4.	Sepsis (Septicemia) 01/01/2023 - "More importantly, CGP42112 significantly improved the survival of rats with sepsis (50% vs. 20% at 24 h after CLP, p < 0.05). " 01/01/2023 - "The protective effects of CGP42112 may be related to anti-inflammatory responses, suggesting that the stimulation of AT2R is a promising therapeutic candidate for the treatment of sepsis."
5.	Brain Ischemia (Cerebral Ischemia) 08/24/2012 - "Secondly, we tested whether CGP42112 is effective when administered systemically in a mouse model of cerebral ischemia. " 08/24/2012 - "Mice treated with CGP42112 (1 mg/kg i.p.) after cerebral ischemia had improved functional outcomes over vehicle-treated mice as well as reduced total and cortical infarct volumes. " 08/24/2012 - "Furthermore, systemic administration of CGP42112 can reduce functional deficits and infarct volume following cerebral ischemia in vivo."

Related Drugs and Biologics

1.	Perindopril
2.	Angiotensin II
3.	Losartan (Cozaar)
4.	Ligands
5.	Type 1 Angiotensin Receptor
6.	Vasopressin Receptors (Arginine Vasopressin Receptor)
7.	Vasopressins (Vasopressin)
8.	Salts
9.	human serelaxin protein
10.	candesartan cilexetil (Amias)

Related Therapies and Procedures

1.	Ganglionectomy
2.	Intra-Articular Injections